Léčivé přípravky s obsahem účinné látky Alirokumab
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| S2026/00267/00 | 07. 04. 2026 | Sanofi s.r.o. | 26 611 079,91 | 23 759 892,78 | 26 611 079,91 | 23 759 892,78 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| S2026/00267/00 | S2026_00267_00 Kupní smlouva Alirokumab CEO SIGNED.pdf | Smlouva | 04. 05. 2026 14:27 | Dokument není zavirovaný | |
| S2026_00267_00 Kupní smlouva Alirokumab.pdf | Blíže nespecifikovaný dokument | 04. 05. 2026 14:28 | Dokument není zavirovaný |
List of Participants
| Show detail | |||||||
|---|---|---|---|---|---|---|---|
| Sanofi s.r.o. | Praha | 26 611 079,91 | 23 759 892,78 | CZK | Yes | Yes |
Written Report - Justification
| Show detail | Justification for using other means of communication for submitting bids instead of electronic means | Justification for not dividing an above-threshold public procurement into lots | Justification for setting requirements for proving turnover in case of proceeding according to Article 78(3), if not stated in the tender documentation |
|---|---|---|---|
| povaha VZ to neumožňuje | nestanoveno |